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INTRODUCTION
Production of reactive species, mostly of oxygen 
(ROS), is an integral part of every aerobic metabo-
lism. Because of the high potential of ROS, especial-
ly very reactive free radicals (FR), to damage vital 
biological systems by forming oxidatively modified 
biomolecules (proteins, lipids, nuclei acids) that dis-
turb their relatioships and organization (Slater, 1987; 
Halliwell and Gutteridge, 1989; Floyd and Carney, 
1992), living organisms have been forced to develop 
an antioxidative defense system (AOS). The human 
AOS has a complex and multilevel organization with 
the role of counteraction this reactivity by prevent-
ing formation or propagation of reactive oxygen and 
nitrogen species and reducing or repairing damage 
already done (Halliwell et al., 1992; Halliwell, 1996; 
Frei, 1999). As a first level of defense, the AOS 
includes enzymes, mostly intracellularly located, 
such as several forms of superoxide dismutase 
(SOD), glutathione peroxidases (GSHPx), gluta-
thione-S-trasferases (GST), and catalase (CAT); a 
group of macromolecules including albumin, ceru-
loplasmin, and ferritin; several small-molecule anti-
oxidants (present extra and intracellularly); includ-
ing reduced glutathione (GSH), ubiquinol-10, uric 
acid, bilirubin, lipoic acid, methionine, and vitamins 
(ascorbic acid, α−tocopherol, β−carotene); and sev-
eral micro or trace elements (Pryor, 1994; Jacob, 
1995). Several hundred small-molecule compounds 
with antioxidant properties are currently recognized 
(Chapple, 1997). Most of them are derived from 
dietary sources (Djujić et al., 2000), but the cell itself 
synthesizes a minority of these molecules, ones such 
as glutathione and NADPH. The AOS has its own 
redox scavenging (injury-repairing) capacity that 
very much depends on the individual’s antioxida-
tive status (from the genetic base to current envi-
ronmental influence). Under normal physiological 
conditions, a balance exists between production 
of ROS and AOS activity. Many factors disturb 
this equilibrium, thereby reducing the organism’s 
defense capacity and allowing uncontrolled oxida-
tion of biomolecules. Such factors include expo-
sure of the organism to environmental toxicants, 
hazardous chemicals, and heavy metals; ionizing 
radiation; miscellaneous xenobiotics; and endog-
enous pathological metabolic changes. Generally, 
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depletion or incapability of the AOS for defense 
leads to a condition in the organism known as “oxi-
dative stress”. Oxidative stress has now been recog-
nized to entail serious pathological changes in the 
organism that are related to more than a hundred 
disease states (Halliwell et al., 1992; Braganza et 
al., 1995) such as atherosclerosis (Witztum, 1994; 
Heinecke, 2003); rheumatoid arthritis (Heliovarra et 
al., 1994); cardiovascular diseases and primary heart 
attacks (Oliver, 1995; Miller, 1997); amyotrophic 
lateral sclerosis (Glabinski et al.,1993); cataract; 
neurodegenerative disorders like Parkinson's disease 
(Olanow and Tatton, 1999); Alzheimer's demen-
tia and strokes (Ikeda and L o n g, 1990); cancers 
(Block, 1992; Afrasyap et al., 1998); and autoim-
mune diseases and factors underlying the aging pro-
cess itself (Harman, 1995; Reiter, 1995). Oxidative 
stress, as a state of imbalance between prooxidative 
and antioxidative processes, can thus be the cause 
and also the consequence of most illnesses. In the 
light of these facts, estimation of the level of oxida-
tive stress and the capacity of the AOS for defense is 
important for health of both the population at large 
and individuals. 
The best way to monitor ROS activity and levels 
of the main AOS components in particular situations 
and obtain a complex picture contributing to health 
control would be by direct measurement. In routine 
practice, most of these methods are still time-con-
suming, labor-intensive, and costly. Moreover, they 
require complicated techniques and suffer from a 
lack of standardization and referent levels. 
For practical reasons and because of the need 
for such data, biochemists have tried to develop a 
one-step method to quantify a body’s antioxidant 
capacity or status. Using bodily fluids, mostly blood, 
different analytical methods for assessing total anti-
oxidant capacity have appeared. These methods 
differ, depending on what technology and which FR 
generator or oxidant has been used. They include 
determination of the total peroxyl radical-trapping 
parameter (TPRAP), the most widely used assay of 
antioxidant capacity during the last decade (Wayner 
et al., 1985); fluorescence-based total antioxidant 
capacity (TAC) (Miller et al., 1993; Ghiselli et al., 
1994); total antioxidant activity (TAA) in a phycoer-
ythrin fluorescence-based assay (Glazer, 1990); total 
antioxidant power (TAOP) or the ferric-reducing 
ability of plasma (FRAP) (Benzie and Strain, 1999; 
Benzie et al., 1993; Cao et al., 1995); total antioxidant 
status (TAS) or Trolox equivalent antioxidant capac-
ity (TEAC) by a colorimetric method (Miller et al., 
1993; Rice-Evans and Miller, 1994; Re et al., 1999); 
and other parameters. In the course of time, most 
of those methods have been improved or modified 
(Johnstone et al., 2006) and have additionally been 
used in the food and cosmetics industries (Wang et 
al., 1996; Arendt et al., 2001) to analyze the antioxi-
dant potential of products for commercial uses. 
The main aim of this study was to present a way 
of monitoring the state of the AOS by estimating 
antioxidant capacity as TAS (e.g., Trolox equivalent 
antioxidant capacity of TEAC) in blood plasma using 
the colorimetric method of Rice-Evans and Miller 
(Rice-Evans and Miller, 1994). This technique mea-
sures the ability of antioxidants in physiological fluids 
to quench absorbance of the FR cation formed by the 
reaction of 2,2-azinobis-(3-ethyl-benzothiazoline-6-
sulfonic acid) (ABTS), a specific chromogene, with 
peroxidase (metmyoglobin) and hydrogen perox-
ide (Miller et al., 1993). Trolox (6-hydroxy-2,5,7,8-
tetramethylchroman-2-carboxylic acid), an analog 
of vitamin E, is used as an antioxidant standard. 
This method was adopted by Randox Laboratories 
(Crumlin, England) for a commercial kit, which is 
also suitable for automatic biochemical analyzers. We 
advocate the addition of TAS analysis to the usual 
biochemical parameters in health control, especially 
for people working in a potentially hazardous envi-
ronment, such analysis being performed by an auto-
matic biochemical analyzer (in our study, one of the 
Daytona type). In addition, we compare our results 
of TAS measurement with results from other labora-
tories applying the same techniques. We also attemp 
to establish correlations between TAS and levels of 
biochemical blood compounds related to AOS capac-
ity (serum total proteins, bilirubin, urea, creatinine, 
and fasting glucose).
MATERIALS AND METHODS
This study was conducted within the frame-
work of periodical regular control of the health of 
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98 males working in the metallurgical industry, 
education, and nuclear research at the Department 
of Radiological Health Protection, Vinča Institute 
of Nuclear Sciences, Belgrade, Serbia. All blood 
sample donors were informed about the objective 
of the study and were asked for their permission 
before taking the blood sample. Personal data were 
considered confidential and were used only for sta-
tistical analysis, such data including gender, age, and 
physicians’ conclusions for statistical evaluations. To 
establish the referent TAS value for the healthy work-
ing male population, individuals with a diagnosis of 
some acute or chronic disease, for example diabetes, 
malignancy, or high blood pressure (systolic blood 
pressure – SBP > 140 mm Hg and diastolic blood 
pressure – DBP > 90 mm Hg), were excluded from 
the group, leaving 72 relevant samples. 
Chemicals for the TAS assay were ones supplied 
with the Randox TAS kit (metmyoglobin, hydrogen 
peroxide, ABTS chromogen, diluting agent, sample 
of control plasma, and Trolox as an equivalent anti-
oxidant capacity standard). Additional chemicals 
and reagents for blood plasma sampling and mea-
surement not supplied by Randox were obtained 
from Sigma-Aldrich (USA).
Samples for plasma TAS were prepared by 
separation of blood elements from heparinized and 
centrifuged (10 min, 4°C, 2500 x g) venous blood 
taken for biochemical analyses during regular peri-
odic health control. Plasma samples were stored 
without further preparation at -20oC until use for 
TAS measurement.
The TAS assay was conducted applying Randox 
TAS kit components with Trolox as an equivalent 
standard (Rice-Evans and Miller, 1994). The assay 
is based on generation of a stable radical cation 
(ABTS•+) from a reaction where metmyoglobin, 
which acts as a peroxidase, in the presence of hydro-
gen peroxide form a radical that interacts with the 
chromogen ABTS. Quenching of absorbance of this 
species at 600 nm by plasma or individual antioxi-
dants can be quantified and then compared to that 
from Trolox as a standard under the same condi-
tions. The results are expressed as mmol Eq Trolox/L 
of plasma (Pl).
The TAS analyses were performed on a new-gen-
eration Daytona (RX) automatic chemical analyzer 
according to instructions provided by the Randox 
Co. The protocol quantified absorbance of plasma 
samples at 600 nm. The Trolox standard and the 
control plasma sample were run at the same time. 
From the same blood samples, blood chemistry, i.e., 
serum concentrations of total protein, cholesterol, 
triglycerides, urea, total bilirubin, creatinine, and 
glucose, as well as the activities of aspartate ami-
notransferase (AST), γ-glutamyltransferase (GGT), 
and alkaline phosphatase (AP), were evaluated on 
the same Daytona automatic analyzer according to 
routine protocols and standards.
For statistical analysis, the obtained values 
of biochemical blood parameters for the analyzed 
group of 86 working males and a referent group 
of 72 subjects at the end were expressed as means 
(AV) ± standard deviation (SD) with the standard 
error of the mean (SE). The parametric coefficient 
of correlation was used to cross-compare TAS val-
ues [mmol/L Pl] of 72 plasma samples with selected 
biochemical parameters of compounds related to 
AOS capacity: total protein (TP), urea, bilirubin 
(TBil), creatinine (Cre), and glucose, with the con-
fidence level estimated by regression analysis (using 
Microcal Origin statistics). The difference between 
two parameters or levels was considered statistically 
significant at p < 0.05.
RESULTS
Measuring of blood plasma samples for TAS was 
performed on a Daytona (RX) automatic chemical 
analyzer using the Randox TAS kit assay with Trolox 
as a standard. Variations were shown to be less than 
3%. The mean TAS level for our group of 86 indi-
viduals (after excluding persons with a diagnosis of 
some acute or chronic disease, for example diabetes, 
malignancy, or unregulated blood pressure) with 
mean age of 47.5 ± 7.5 (31-60) was 1.779 ± 0.103 
(0.011) mmol Trolox Eq/L Pl (min 1.40 and max 
2.06 mmol/L). This mean TAS level was within the 
established normal range of 1.4-1.9 mmol/L given 
by the Randox protocol. Only six values exceeded 
our normal range, and that represents 7% of the 
analyzed samples.
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Other relevant biochemical parameters mea-
sured from the same blood sample on the same 
Daytona automatic chemical analyzer showed the 
following AV ± SD (SE) values: TBil, 18.52 ± 7.79 
(0.85) µmol/L; urea, 5.86 ± 1.40 (0.15) mmol/L; TP, 
79.1 ± 8.5 (0.9) g/L; Cre, 108.9 ± 14.9 (1.6) µmol/L; 
and glucose, 5.57 ± 0.965 (0.106) mmol/L. The group 
of working males also had SBP 127.9 ± 11 (1.25) and 
DBP 80.8 ± 5.5 (0.69). Among them, seven men 
(8%) were considered to have mild hypertension 
(SBP > 140 mm Hg and DBP > 90 mm Hg).
To establish the referent TAS value for healthy 
working males coming in for regular health control, 
we excluded from the analyzed group individuals 
with higher blood pressure (leaving only normoten-
sive subjects) and with extreme levels of more than 
two biochemical parameters, which left us with 72 
relevant samples. Estimated TAS values, levels of 
some biochemical factors, and correlations of TAS 
with them are given in Table 1. The obtained average 
TAS value of 1.768 ± 0.102 (0.012) mmol/L Pl for 
this referent normotensive group was not signifi-
cantly different from a previous larger group, which 
had the same range of values (1.40-2.06 mmol/L). 
The other TAS-relevant biochemical parameters 
also exhibited no significant difference from previ-
ous data, but had better homogeneity within the 
group, as was expected. The largest variation was 
found in the case of TBil (range 6.2-39.5 mmol/L), 
where 19 (26%) samples were within the overall ref-
erent range of 0-20.5 mmol/L. In the case of glucose, 
16 samples (22%) were within the overall normal 
range of 4.2-6.4 mmol/L.
Calculated correlations between TAS and the 
other biochemical parameters are also presented in 
Table 1. Positive correlations, statistically significant 
as determined by regression analysis, were found be-
tween TAS and TBil (R = 0.243, p < 0.01), TP (R = 
0.458, p < 0.001), and Cre (R = 0.325, p < 0.002). 
Between TAS and glucose, DBP, and SBP, we found 
negative or inverse correlations of R = - 0.209, p < 
0.05; R = - 0.286, p < 0.005; and R = - 0.303, p < 
0.005, respectively. There was no significant corre-
lation between TAS and urea, only a positive trend 
without significance.
DISCUSSION
As it has been already mentioned, there is a con-
stantly increasing need for new ways of monitoring 
human health to achieve better and faster control 
Table 1. Blood plasma or serum mean levels (AV) of TAS and relevant biochemical parameters with correlations to TAS for healthy 
working men. Plasma TAS, serum total protein, urea, bilirubin, creatinine, and glucose were expressed as mean levels of 72 samples, 
AV ± SD (SE). Differences at the level of P < 0.05 are considered to be statistically significant. N.S. - non significant correlation.
AV ± SD
(SE) Correlation (R) with TAS  P <
   Age 
   (years) 47.8 ± 7.5                 
   TAS
   [mmol/L Pl] 
1.768 ± 0.102
(0.012)  
   Bilirubin total 
    [µmol/L]
17.65 ± 7.66
(0.91)   
0.243 0.01
    Urea  
   [mmol/L]
5.84 ± 1.35
(0.15)  
- 0.085 N.S.
   Proteins, total 
    [g/L]
78.0 ± 7.6
(0.9)   
0.458 0.001
   Creatinine 
    [µmol/L]
106.8 ± 12.5
(1.5) 
0.325 0.002
   Glucose 
    [mmol/L]
5.66 ± 0.93
(0.52) 
- 0.209 0.01
   Blood pressure
   [mm Hg]
Sys 127.3 ± 4.4
(0.53)
 Dia 79.5 ± 4.5
(0.53)   
- 0.286
- 0.303
0.005
0.005
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and assist in diagnosing alterations. Blood TAS 
analysis as a measure of antioxidative defense system 
capacity is a relatively noninvasive method which 
we believe can contribute to that aim. We agree that 
quantitatively measuring the antioxidant capacity 
or antioxidant power of each relevant compound 
separately (or the cumulative effect of several) could 
provide more complete information about the anti-
oxidant state of individuals. However, in routine 
health care, one-way brief analysis of TAS and other 
biochemical parameters can be more useful for indi-
viduals and populations, especially if estimated by 
automatic analyzers (Lantos et al., 1997; Ching et al., 
2002; Erel, 2004; Johnstone et al., 2006).
After comparing several methods of assessing 
the total antioxidant capacity of human serum or 
plasma, we chose a method based on estimation of 
blood TAS with Trolox as an equivalent standard 
(Miller et al., 1993; Rice-Evans and Miller, 1994) 
because it can be used with an automatic chemical 
analyzer as a micromethod (if utilizes only a few µL 
of sample material) and has standardization estab-
lished by a world-renowned laboratory (Randox). 
The critical reviews of this method pointed out 
a few problems related to technical performance. 
Schofield and Braganza (1996) demonstrated varia-
tions in serum TAS levels with reading time. Our 
results obtained using the manual variant of this 
method are in agreement with this observation 
(unpublished data). The fact is that TAS represents 
the total contribution from a wide range of plasma 
components with antioxidant properties. The com-
bined antioxidant capacity of uric acid and albumin 
accounts for 51% of the total, the remaining activity 
being a measure of the combined power of other 
plasma antioxidants like creatinine, tocopherols, 
and ascorbate. The antioxidative rates of plasma 
proteins are not as high as that of Trolox  as a pure 
substance. However, Trolox has been used as a tra-
ditional standard in measuring TAS. We agree with 
Lamont et al. (1997) in asserting that if estimation 
of serum TAS with an automatic analyzer employs 
standardized 3-min reading time in the same highly 
controlled conditions applied to all samples, varia-
tions depending on reading time are not relevant. 
Also, the observation that dilution of samples results 
in an increase in the TAS level is correct, but in 
practice this is a negligible disadvantage (a serum or 
plasma TAS value > 2.5 mmol/L is the linear limit 
of method). Same critical comments have called 
attention to the fact that the plasma sample itself 
can influence the reliability of TAS measurement. 
The presence of lipids in the blood and in blood 
plasma (> 10.0 g/L), because of their turbidity, leads 
to increased absorbance of samples. Also, because of 
their color, icteric serum and haemoglobin (hemoly-
sis causes the release of constituents from red blood 
cells) show a weak increase of absorbance in TAS 
measurement. The application of a micromethod 
employing an automatic analyzer reduces those 
errors to a great extent.
In our study, all extreme conditions pertaining 
to plasma samples or other conditions were avoided 
because we tried to establish the referent range of 
TAS in plasma of the normal working male. In auto-
matic sampling, the plasma’s relative dilution is high 
already, and the concentration of anticoagulants 
therefore is very low and does not affect incuba-
tion medium components. Thus, the anticoagulants 
did not act as either prooxidants or antioxidants. 
Analyses of the Trolox standard and referent plasma 
from the Randox kit were performed in triplicate 
with good agreement. With the employed method, 
there was no statistically significant difference of 
TAS values between serum and plasma (despite the 
difference in protein concentration.
The Randox TAS kit that we used and the auto-
matic micromethod of estimation (by a Daytona 
chemical analyzer) allow various laboratories to 
perform TAS analyses under the same analytical 
conditions, reducing errors stemming from analyti-
cal procedure and permitting valid comparison of 
results. The obtained mean TAS value (1.768 ± 0.102 
mmol/L of Pl) was in the range of data obtained by 
other authors employing the same method, viz., 
1.41 ± 0.12  mmol/L (Cao and Prior, 1998) and 
1.48 to 1.63 mmol/L (Lamont et al., 1997), and in 
the upper part of the Randox reference range of 
1.30-1.77 mmol/L of Pl, but was 39% higher than 
that obtained by Koracevic et al. (2001) (1.08 ± 0.28 
mmol/L of Pl). The differences in mean TAS levels 
may result from the choice of groups in establishing 
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the control range (sex, mean age, environmental 
factors, life style). The applied method is precise 
enough to distinguish various populations and their 
plasma TAS values.
The correlations of mean TAS values to levels 
of relevant biochemical parameters (TP, creatinine, 
glucose, SBP, and DBP) for our working populatoin 
were also in good agreement with results obtained by 
other authors (Lamont et al., 1997), with significance 
demonstrated by regression analysis. Unexpectedly, 
we found no correlation between TAS and mean 
urea concentrations in our male working group, 
although urea can be considered one of the main 
antioxidant compounds in blood plasma, along with 
albumin and ascorbate. The explanation could lie in 
the applied method of uric acid estimation or in the 
kind of working group we chose for TAS analysis. 
Further epidemiological investigation and TAS esti-
mation of other populations are needed to establish 
more TAS referent ranges.
CONCLUSIONS
Our estimation of blood plasma TAS levels in a 
group of working people using established techni-
cal and chemical procedure (Randox TAS assay) 
and an automated chemical analyzer (Daytona RX) 
showed that TAS as a biochemical parameter can 
be easily included in regular health control of our 
working population and is additionally useful in 
medical diagnostics. This method of TAS analysis 
is easily performed, rapid, and reliable, and only 
small samples of biological material are needed 
for the analyses. Its low-cost makes it practical for 
routine measurement in our conditions. The results 
are comparable with standards from other countries 
and are correlated with related biochemical param-
eters already included in health control.
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УКУПНИ АНТИОКСИДАНТНИ СТАТУС (TAS) КАО БИОХЕМИЈСКИ ПАРАМЕТАР У 
ЗДРАВСТВЕНОЈ КОНТРОЛИ ЗАПОСЛЕНИХ
ОЛГА ЈОЗАНОВ-СТАНКОВ1, ЈОВАНКА ЂУРИЋ2, БРАНИСЛАВА ДОБУТОВИЋ1 и ЕСМА Р. ИСЕНОВИЋ1
1Лабораторија за радиобиологију и молекуларну генетику,
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Но­ва сазнања о­ уло­зи сло­бо­д­но­рад­икалске 
равно­теже у успо­стављању и о­д­ржавању хо­мео­­
стазе у о­рганизму усло­вила су по­требу д­а се о­д­ре­
ђивање параметара система заштите о­д­ о­ксид­атив­
них о­штећења увед­е међу о­бавезне био­хемиј­ске 
анализе при перио­д­ич­но­м зд­равствено­м преглед­у 
запо­слених, наро­ч­ито­ о­них ко­ј­и рад­е у по­тенциј­ал­
но­ штетним усло­вима. У о­во­м рад­у желели смо­ 
д­а укажемо­ на по­требу укључ­ења анализе укуп­
но­г антио­ксид­антно­г статуса (To­tal An­ti­o­xi­dan­t 
Status, TAS) из крвне плазме међу био­хемиј­ске 
параметре при зд­равствено­м преглед­у по­пулациј­е 
запо­слених. Са циљем д­а се устано­ве референтне 
вред­но­сти TAS, изд­во­ј­ена ј­е група зд­равих, но­р­
мо­тензивних о­со­ба мушко­г по­ла. Мерења ниво­а 
TAS у плазми рађена су спектро­фо­то­метриј­ско­м 
мето­д­о­м ко­ристећи д­иј­агно­стич­ки ко­мплет фирме 
Ran­do­x Lab. En­glan­d, на ауто­матско­м клинич­ко­м 
хемиј­ско­м анализато­ру но­виј­е генерациј­е Dayto­n­a 
RX, ко­ј­и о­мо­гућава д­о­бру прецизно­ст и репро­д­у­
цибилно­ст ко­ришћене микро­мето­д­е. Од­ређена ј­е 
и ко­релациј­а са д­ругим за TAS релевантним био­­
хемиј­ским параметрима, ко­ј­и су се станд­ард­но­ 
о­д­ређивали из истих узо­рака крви при преглед­у 
запо­слених (билирубин, уреа, укупни про­теини, 
креатинин, глуко­за, крвни притисак). Вред­но­сти 
TAS параметра д­о­прино­се ко­мплетниј­ем мо­нито­­
рингу зд­равља како­ по­ј­ед­инца, тако­ и о­д­ређене 
по­пулациј­е, наро­ч­ито­ у вези утицај­а усло­ва рад­а 
и живо­тне сред­ине.
